ReviewFrontiers in immunology2022
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 50 citations in OpenAlex.
- Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications.Cell reports methods · 2026Article
- Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.Cancer cell · 2026Article
- Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial.Cancer immunology, immunotherapy : CII · 2026Article
- Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers.Annals of hematology · 2026Review
- Review
- One-step knock-in CAR constructs in human NK cells enable scalable, TGFβ1-resistant immunotherapy for solid tumors.Theranostics · 2026Article
- The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatment.Frontiers in molecular medicine · 2026Review
- CXCL10-induced chemotaxis ofMolecular therapy. Oncology · 2025Article
- A Scalable Protocol for Ex Vivo Production of CAR-Engineered Human NK Cells.Methods and protocols · 2025Article
- Mechanoregulation of lymphocyte cytotoxicity.Nature reviews. Immunology · 2025Review
- The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Biomarker research · 2025Review
- IPSC‑derived NK cells for immunotherapy and therapeutic perspective (Review).Molecular medicine reports · 2025Review
- Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review.Discover oncology · 2025Review
- The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances.Biomedicines · 2025Review
- Engineering innate immune cells for cancer immunotherapy.Nature biotechnology · 2025Review
- Characterization and effective expansion of CD4Molecular therapy. Methods & clinical development · 2025Article
- CAR-NK cell therapy: promise and challenges in solid tumors.Frontiers in immunology · 2025Review
- GMP Manufacturing of Allogenic iPSC-NK Cells for Immunotherapy.Advances in experimental medicine and biology · 2025Review
- Article
- CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer cells constitute a part of the innate immune system that mediates an effective immune response towards virus-infected and malignant cells. In recent years, research has focused on exploring and advancing NK cells as an active immunotherapy platform. Despite major advances, there are several key challenges that need to be addressed for the effective translation of NK cell research to clinical applications. This review highlights some of these challenges and the innovative strategies being developed to overcome them, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.